Genmab — Juni 2023

[E_L]

TRiMM-2: Response Rate of 78% Seen in Patients Who Receive Talquetamab With Subcutaneous Daratumumab for Multiple Myleoma https://www.ajmc.com/view/trimm-2-response-rate-of-78-seen-in-patients-who-receive-talquetamab-with-subcutaneous-daratumumab-for-multiple-myleoma

[E_L]

Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Updated TRIMM-2 Results https://www.congresshub.com/Oncology/AM2023/Talquetamab/Dholaria

[E_L]

Dual Bispecific Combination Teclistamab/Talquetamab Displays High Activity in RRMM https://www.targetedonc.com/view/dual-bispecific-combination-teclistamab-talquetamab-displays-high-activity-in-rrmm

[E_L]

https://twitter.com/jmikhaelmd/status/1665068913296658432

[E_L]

First Results From the RedirecTT-1 Study With Teclistamab + Talquetamab Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma https://www.congresshub.com/Oncology/AM2023/Teclistamab/Cohen

[Bulder]

Not much difference between Tal mono and Tal + dara in RR MM?

[Bulder]

Thx E L

[E_L]

https://www.jnj.com/new-long-term-data-from-the-chrysalis-study-show-median-progression-free-survival-not-reached-after-33-6-months-of-follow-up-with-first-line-use-of-rybrevant-amivantamab-vmjw-and-lazertinib-combination-therapy-in-patients-with-treatment-naive-egfr-mutated-advanced-non-small-cell-lung-cancer

[E_L]

New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer

[peter12]

Wau det lyder godt Det er i 1L ?

[Bulder]

Ja, her begynder det at ligne noget. Desværre dog kun fase 1.

[peter12]

Der kører også fase 3 studier https://www.jnj.com/new-long-term-data-from-the-chrysalis-study-show-median-progression-free-survival-not-reached-after-33-6-months-of-follow-up-with-first-line-use-of-rybrevant-amivantamab-vmjw-and-lazertinib-combination-therapy-in-patients-with-treatment-naive-egfr-mutated-advanced-non-small-cell-lung-cancer

[E_L]

the amivantamab posters are now all available https://www.congresshub.com/Oncology/AM2023

[E_L]

SC dosing of amivantamab significantly improved IRR safety profile (16% vs 67% for IV) https://www.congresshub.com/Oncology/AM2023/Amivantamab/Minchom#interactive_pdf That should make this drug much much more tolerable

[Bulder]

Peter 23:40: ja men jeg tvivler på at Mariposa når med på asco til næste år.

[E_L]

another Hemophilia trial for Daratumumab ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor https://www.clinicaltrials.gov/ct2/show/NCT05888870

[E_L]

Janssen Presents Longer-Term Data for TECVAYLI (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma https://www.jnj.com/janssen-presents-longer-term-data-for-tecvayli-teclistamab-cqyv-showing-a-duration-of-response-of-22-months-in-patients-with-relapsed-or-refractory-multiple-myeloma

[E_L]

J&J’s multiple myeloma combo produces déjà vu with 96% Carvykti-like response https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response

[Bulder]

Jamen er det ikke hvad vi altid har sagt? Og når de så lægger dara oveni, så får vi ORR-rater på 105%. Jeg tør slet ikke tænke på, hvad der vi når op på, når superdara kommer.

[bibob]

Fra ASCO. https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech+Tracker&oly_enc_id=6900G6464778A3A